Vivos Therapeutics, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held on November 26, 2024. The filing was submitted on November 27, 2024. As of the record date (October 4, 2024), there were 4,765,300 shares of common stock entitled to vote. Approximately 2,695,565 shares were present or represented by proxy, constituting a quorum.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes and Voting Results
Stockholders voted on three primary proposals:
- Election of Directors: Six nominees (R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow, and Dr. Matthew Thompson) were elected to one-year terms. Significant broker non-votes (1,415,480 shares) were recorded for all director nominees.
- 2024 Omnibus Equity Incentive Plan: The plan was approved. Voting results were 957,268 shares for, 313,560 shares against, and 17,747 shares abstaining.
- Ratification of Auditors: The appointment of Moss Adams LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. Voting results were 2,496,723 shares for, 162,219 shares against, and 35,623 shares abstaining.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial outlook, guidance, risks, contingencies, or unusual items. It is strictly limited to the disclosure of stockholder voting outcomes.
Key Facts for Investor Verification
- Verify the specific terms and share reserve limits of the newly approved 2024 Omnibus Equity Incentive Plan.
- Note the high volume of broker non-votes (1,415,480 shares) on the director election, which may indicate significant institutional holdings where brokers lacked discretionary voting authority.
- Confirm the composition of the Board of Directors for the upcoming term ending at the 2025 Annual Meeting.
- Review the full proxy statement for detailed biographies of the elected directors and the rationale for the equity plan.